Bicara Therapeutics Inc. (BCAX) stock
BCAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.38−0.22 (-2.29%)
Close on Nov 18, 2026Market cap $620.70MP/E –Yield –
Bicara Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Bicara Therapeutics's free cash flow for the twelve months ending Sep 30, 2026 was -$162.75M. For fiscal 2025 it was -$107.11M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$107.11M | – |
| FY2024 | Dec 31, 2024 | -$74.82M | – |
| FY2023 | Dec 31, 2023 | -$46.21M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$56.79M | – |
| Q2 FY2026 | Jun 30, 2026 | -$44.27M | – |
| Q1 FY2026 | Mar 31, 2026 | -$37.57M | – |
| Q4 FY2025 | Dec 31, 2025 | -$24.12M | – |
| Q3 FY2025 | Sep 30, 2025 | -$29.29M | – |
| Q2 FY2025 | Jun 30, 2025 | -$25.59M | – |
| Q1 FY2025 | Mar 31, 2025 | -$28.11M | – |
| Q4 FY2024 | Dec 31, 2024 | -$30.07M | – |
| Q3 FY2024 | Sep 30, 2024 | -$17.23M | – |
| Q2 FY2024 | Jun 30, 2024 | -$12.93M | – |
| Q1 FY2024 | Mar 31, 2024 | -$14.59M | – |
| Q4 FY2023 | Dec 31, 2023 | -$8.47M | – |
See a number that looks wrong?